Comparative study of micro-transplantation from HLA fully mismatched unrelated and partly matched related donors in acute myeloid leukemia

American Journal of Hematology
Kai-Xun HuYi Wang

Abstract

Micro-transplantation (MST) by chemotherapy, combined with granulocyte colony-stimulating factor-mobilized peripheral blood stem cell (GPBSC) infusion, from an HLA partial matched related donor has shown some encouraging effective therapy for acute myeloid leukemia (AML). However, the outcome of human leukocyte antigen (HLA) fully mismatched unrelated donor-derived MST in such patients is still unknown. In the present study, we compared the efficacy of HLA fully mismatched unrelated donor-derived MST, and partly matched related donor-derived MST, in AML of 126 patients from two centers in China, These patients, aged 16 to 65 years, were given three or four courses of MST, which consisted of a high dosage cytarabine followed by GPBSC from unrelated donor or related donor. There was a statistically significant difference in 3-year leukemia-free survival (LFS) and 3-year overall survival (OS) between the unrelated and the related group. The non-treatment-related mortality (NRM) rates of patients, and other adverse complications, were no different in the two groups. In conclusion, unrelated donor-derived MST is believed to be a safe treatment, with efficacy similar to or higher than related donor-derived MST. This result provides s...Continue Reading

References

Dec 16, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bruce D ChesonUNKNOWN International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards
Jul 16, 2010·International Journal of Laboratory Hematology·C C YinC E Bueso-Ramos
Mar 26, 2011·Blood·Gunnar Juliusson, UNKNOWN Swedish AML Group
Oct 10, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Mei GuoHui-Sheng Ai
Jul 3, 2013·Cytogenetic and Genome Research·A SimonsR J Hastings
Feb 13, 2017·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Yu ZhuSixuan Qian
Feb 24, 2017·Current Hematologic Malignancy Reports·Kevin A DavidRoger Strair
Jun 13, 2017·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Müberra AhciKatharina Fleischhauer
Sep 16, 2017·Placenta·H S Gammill, W E Harrington
Feb 6, 2018·Physical Review Letters·B P AbbottUNKNOWN LIGO Scientific Collaboration and Virgo Collaboration
Mar 21, 2018·Leukemia Research Reports·Nathan PunwaniGiridharan Ramsingh
Jul 18, 2018·American Journal of Hematology·Amir T FathiYi-Bin Chen
Aug 28, 2018·Current Opinion in Hematology·Bo CaiHuisheng Ai

❮ Previous
Next ❯

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.